Subscribe to Newsletter
Discovery & Development Clinical Trials, Vaccines

Hope in the Fight Against Malaria

Are we getting closer to eradicating malaria? A team of US scientists led by Patrick E. Duffy at NIAID and Stephen L. Hoffman at Sanaria have conducted phase I trials of a malaria vaccine (PfSPZ) that offers a strong, durable protection for patients exposed to the disease (1). The vaccine is composed of sporozoites (the form of the malaria parasite transmitted by mosquito bites) and is combined with either pyrimethamine or chloroquine.

Of the two combinations, chloroquine appears to perform best. Among volunteers who received the highest PfSPZ dosage combined with pyrimethamine, 77.8 percent were protected from heterologous challenge, whereas 100 percent of those who received the higher PfSPZ dosage were protected.

A phase II trial is now underway in Mali, where malaria is endemic. At present no malaria vaccine is in widespread use, but the initial success of PfSPZ points to a promising future.

Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. A Mwakingwe-Omari et al., Nature (2021).  DOI: https://doi.org/10.1038/s41586-021-03684-z.
About the Author
Angus Stewart

Associate Editor of The Medicine Maker

Between studying for my English undergrad and Publishing master's degrees I was out in Shanghai, teaching, learning, and getting extremely lost. Now I'm expanding my mind down a rather different rabbit hole: the pharmaceutical industry. Outside of this job I read mountains of fiction and philosophy, and I must say, it's very hard to tell who's sharper: the literati, or the medicine makers.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register